Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.

Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting ...

Operator: Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference ...

Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

(SHOP) was up 25.3% in pre-market trading, and Travere Therapeutics Inc. (TVTX) was up 12.7%.

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...